Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Radiology and Oncology
Volume 50 (2016): Issue 1 (March 2016)
Open Access
Cerebral toxoplasmosis in a diffuse large B cell lymphoma patient
Lina Savsek
Lina Savsek
and
Tanja Ros Opaskar
Tanja Ros Opaskar
| Feb 16, 2016
Radiology and Oncology
Volume 50 (2016): Issue 1 (March 2016)
About this article
Previous Article
Next Article
Abstract
Article
Figures & Tables
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Article Category:
Case Report
Published Online:
Feb 16, 2016
Page range:
87 - 93
Received:
May 27, 2014
Accepted:
Aug 21, 2014
DOI:
https://doi.org/10.1515/raon-2014-0042
© 2016 Radiol Oncol
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1.
(A) MRI at time of diagnosis demonstrating multiple T2 and (B) fluid attenuated inversion recovery (FLAIR) hyperintense parenchymal lesions, located in both cerebral and cerebellar hemispheres, with mild surrounding edema. (C) On T1 sequences, these lesions were hypointense. (D) After contrast administration, only moderate rim enhancement was seen.
Figure 2.
Full body 18F-FDG PET/CT revealing focal hypometabolism, corresponding to toxoplasma lesions. The largest lesion is seen in the right occipital lobe.
Figure 3.
Lesion size and edema reduction after 6 weeks of intensive antibiotic therapy, as demonstrated by (A) fluid attenuated inversion recovery (FLAIR) and (B) T1 sequence.
Figure 4.
Follow-up MRI after 4 months reveals further reduction of lesion size. (A) T1 sequence + gadolinium, (B) T2 sequence.